Chantal Pharmaceutical's cyoctol
Executive Summary
Firm announces IND approval to begin clinicals for cyoctol use in the treatment of male pattern baldness. Initial testing will be conducted at UCLA. Chantal described cyoctol as a synthetic, nonsteroidal anti-androgen that is part of a series of Chantal compounds known as X-Androns. Clinicals are also underway investigating cyoctol use in treatment of acne vulgaris and the company plans to file an IND in 1987 for keloid scar prevention ("The Pink Sheet" Oct. 13, T&G-7).
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.